Literature DB >> 15272050

Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo.

Yoshiko Minakuchi1, Fumitaka Takeshita, Nobuyoshi Kosaka, Hideo Sasaki, Yusuke Yamamoto, Makiko Kouno, Kimi Honma, Shunji Nagahara, Koji Hanai, Akihiko Sano, Takashi Kato, Masaaki Terada, Takahiro Ochiya.   

Abstract

Silencing gene expression by siRNAs is rapidly becoming a powerful tool for the genetic analysis of mammalian cells. However, the rapid degradation of siRNA and the limited duration of its action call for an efficient delivery technology. Accordingly, we describe here that Atelocollagen complexed with siRNA is resistant to nucleases and is efficiently transduced into cells, thereby allowing long-term gene silencing. Site-specific in vivo administration of an anti-luciferase siRNA/Atelocollagen complex reduced luciferase expression in a xenografted tumor. Furthermore, Atelocollagen-mediated transfer of siRNA in vivo showed efficient inhibition of tumor growth in an orthotopic xenograft model of a human non-seminomatous germ cell tumor. Thus, for clinical applications of siRNA, an Atelocollagen-based non-viral delivery method could be a reliable approach to achieve maximal function of siRNA in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15272050      PMCID: PMC506824          DOI: 10.1093/nar/gnh093

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  31 in total

1.  New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet.

Authors:  T Ochiya; Y Takahama; S Nagahara; Y Sumita; A Hisada; H Itoh; Y Nagai; M Terada
Journal:  Nat Med       Date:  1999-06       Impact factor: 53.440

Review 2.  Gene silencing mediated by small interfering RNAs in mammalian cells.

Authors:  Michaela Scherr; Michael A Morgan; Matthias Eder
Journal:  Curr Med Chem       Date:  2003-02       Impact factor: 4.530

3.  Screening for gene function in chicken embryo using RNAi and electroporation.

Authors:  Vladimir Pekarik; Dimitris Bourikas; Nicola Miglino; Pascal Joset; Stephan Preiswerk; Esther T Stoeckli
Journal:  Nat Biotechnol       Date:  2002-12-23       Impact factor: 54.908

4.  Effective expression of small interfering RNA in human cells.

Authors:  Cynthia P Paul; Paul D Good; Ira Winer; David R Engelke
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

5.  Small interfering RNA and gene silencing in transgenic mice and rats.

Authors:  Hidetoshi Hasuwa; Kazuhiro Kaseda; Thorbjorg Einarsdottir; Masaru Okabe
Journal:  FEBS Lett       Date:  2002-12-04       Impact factor: 4.124

6.  A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference.

Authors:  Douglas A Rubinson; Christopher P Dillon; Adam V Kwiatkowski; Claudia Sievers; Lili Yang; Johnny Kopinja; Dina L Rooney; Mingdi Zhang; Melanie M Ihrig; Michael T McManus; Frank B Gertler; Martin L Scott; Luk Van Parijs
Journal:  Nat Genet       Date:  2003-02-18       Impact factor: 38.330

7.  siRNA-mediated gene silencing in vitro and in vivo.

Authors:  Haibin Xia; Qinwen Mao; Henry L Paulson; Beverly L Davidson
Journal:  Nat Biotechnol       Date:  2002-09-16       Impact factor: 54.908

8.  RNA interference targeting Fas protects mice from fulminant hepatitis.

Authors:  Erwei Song; Sang-Kyung Lee; Jie Wang; Nedim Ince; Nengtai Ouyang; Jun Min; Jisheng Chen; Premlata Shankar; Judy Lieberman
Journal:  Nat Med       Date:  2003-02-10       Impact factor: 53.440

9.  Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo.

Authors:  Jean-Rémi Bertrand; Mireille Pottier; Antoine Vekris; Paule Opolon; Andrei Maksimenko; Claude Malvy
Journal:  Biochem Biophys Res Commun       Date:  2002-08-30       Impact factor: 3.575

10.  An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo.

Authors:  Michael T Hemann; Jordan S Fridman; Jack T Zilfou; Eva Hernando; Patrick J Paddison; Carlos Cordon-Cardo; Gregory J Hannon; Scott W Lowe
Journal:  Nat Genet       Date:  2003-02-03       Impact factor: 38.330

View more
  83 in total

Review 1.  RNA interference and cancer therapy.

Authors:  Zhaohui Wang; Donald D Rao; Neil Senzer; John Nemunaitis
Journal:  Pharm Res       Date:  2011-10-19       Impact factor: 4.200

Review 2.  Preclinical and clinical development of siRNA-based therapeutics.

Authors:  Gulnihal Ozcan; Bulent Ozpolat; Robert L Coleman; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Adv Drug Deliv Rev       Date:  2015-02-07       Impact factor: 15.470

Review 3.  Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides.

Authors:  Johannes Winkler
Journal:  Ther Deliv       Date:  2011-07

Review 4.  Nonviral delivery of synthetic siRNAs in vivo.

Authors:  Saghir Akhtar; Ibrahim F Benter
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 5.  Matrices and scaffolds for DNA delivery in tissue engineering.

Authors:  Laura De Laporte; Lonnie D Shea
Journal:  Adv Drug Deliv Rev       Date:  2007-04-14       Impact factor: 15.470

Review 6.  Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies.

Authors:  Ravinay Bhindi; Roger G Fahmy; Harry C Lowe; Colin N Chesterman; Crispin R Dass; Murray J Cairns; Edward G Saravolac; Lun-Quan Sun; Levon M Khachigian
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

Review 7.  Therapeutic regulation of gene expression in the inner ear using RNA interference.

Authors:  Yukihide Maeda; Abraham M Sheffield; Richard J H Smith
Journal:  Adv Otorhinolaryngol       Date:  2009-06-02

8.  Increased RNAi is related to intracellular release of siRNA via a covalently attached signal peptide.

Authors:  Anke Detzer; Marita Overhoff; Winfried Wünsche; Maria Rompf; John J Turner; Gabriela D Ivanova; Michael J Gait; Georg Sczakiel
Journal:  RNA       Date:  2009-02-18       Impact factor: 4.942

Review 9.  Liposomal siRNA nanocarriers for cancer therapy.

Authors:  Bulent Ozpolat; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Adv Drug Deliv Rev       Date:  2013-12-30       Impact factor: 15.470

10.  Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells.

Authors:  Hiroshi Tazawa; Naoto Tsuchiya; Masashi Izumiya; Hitoshi Nakagama
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.